Dr Girard on the Efficacy of First-Line Amivantamab Plus Che

Nicolas Girard, MD, PhD, discusses primary efficacy results from the phase 3 PAPILLON trial of amivantamab plus chemotherapy in EGFR exon 20 insertion–mutated advanced non–small cell lung cancer.

Related Keywords

Nicolas Girard , Institut Curie , Versailles Saint Quentin University , Curie Montsouris Thorax Institute , Respiratory Medicine , Onclive Tv , Nsclc , Amivantamab , Papillon Trial ,